Objective: To examine the consequences of antenatal betamethasone (AB) exposure on postnatal stress regulation.
Introduction
Prenatal exposure to elevated levels of glucocorticoids (GCs) has life-long consequences for emotion and stress regulation, cognitive functioning, and brain development in a variety of species. 1 This issue is critical because synthetic GCs, such as betamethasone, are widely administered to pregnant woman at risk for premature delivery, 2 with unknown consequences for the development of their offspring. Treatment with GCs promotes lung development and survival among premature infants born before 34 weeks of gestation, 2 but major concerns have risen about the lasting impact of GC treatment on development. 1 Animal models indicate that a primary effect of prenatal GC exposure is dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, one of the body's major stress regulatory systems, which may be a conduit for the effects of GC treatment on health and development. Despite significant evidence from the animal literature that prenatal exposure to GCs has a persisting influence on the HPA axis, there have been few studies of this phenomenon with humans. 3 Activation of the HPA axis is critical to maintain homeostasis in response to stress. 4 Both full-term and preterm newborns, without GC treatment, respond to painful stressors with an increase in cortisol production, as indicated by salivary or serum concentrations. 5, 6 This is thought to be an appropriate response given the role that cortisol plays in mobilizing resources to manage physiologic challenges.
A series of studies have demonstrated that baseline cortisol levels are suppressed during the first postnatal week and then return to normal levels in preterm infants exposed to antenatal GC therapy. [7] [8] [9] However, those studies did not assess the responsiveness of the system to a physiologic challenge and thus did not evaluate the axis' ability to react in its normal biological role. Other studies suggest that prenatal GC treatment suppresses the ability to increase cortisol production in response to a physiologic challenge or CRH stimulation, but these studies only assessed the infants during the first postnatal week 5, 10 and did not assess how long this suppression persists. Thus, the longer-term consequences of prenatal GC treatment for regulation of the HPA axis in response to commonly encountered physiologic challenges have yet to be examined in the human infant. Determining the postnatal duration of this suppression may help define a period of vulnerability of premature infants to more life-threatening physiologic stressors in the NICU and following discharge.
The current study was designed to examine the impact of a single course of antenatal betamethasone (AB) on the ability of premature infants born at 28-30 weeks of gestation to respond with an increase in cortisol to an acute physiological stressor, a heelstick blood draw, up to 4-6 weeks after exposure. This stressor was selected because it reliably elicits a significant increase in cortisol production, as compared to baseline levels, in both fullterm and preterm infants without prenatal GC treatment. 5, 6 We hypothesized that (1) infants in the AB group would fail to increase cortisol in response to the heelstick during the first postnatal week, (2) the cortisol response would remain suppressed 4-6 weeks later and (3) the effects of AB would prove to be specific to the HPA axis and thus, that both groups would show similar increases in heart rate (HR) and behavioral state in response to these events.
Methods

Participants
The Institutional Review Boards for protection of human subjects of both institutions approved all aspects of the study protocol. Informed consent was obtained from one of the parents prior to the infant's enrollment in this study. Consent was obtained from 90% of parents whose participation was solicited.
The study sample comprised 23 participants (13 girls and 10 boys) who were born at Fairview University Medical Center or Hennepin County Medical Center in Minneapolis, Minnesota. Infants who met screening criteria were recruited serially into two groups. The experimental AB group included fourteen premature infants between 28 and 30 (mean ¼ 29.3, s.d. ¼ 0.2) weeks gestational age at birth whose mothers received a single course of AB treatment (12 mg/dose for two doses), whose parent gave consent for the study and who subsequently had no postnatal illness. This gestational age range was selected to maximize the chances that there would be no postnatal stress due to illness at the first measurement (e.g. in contrast to 24-28 weeks' gestation) and that the infants would still be in the hospital 4-6 weeks later for longitudinal assessment and for comparison to the baseline findings following birth. In this cohort, the second dose of AB was given between 1 and 9 days prior to delivery (mean ¼ 5.1, s.d. ¼ 2.8). A No AB control group of equal gestational age was considered and rejected because of the scarcity of 28-30 week GA infants not exposed to AB who also did not have significant neonatal illness. Instead, we compared the AB group to a comparison group of nine premature infants born at 33.7 (s.d. ¼ 0.5) weeks of gestation without AB treatment who were not ill in the postnatal period. This group's neonatal data have been previously reported 5 and are used here to provide a postconceptional age-matched comparison group for the follow-up assessment of the experimental group.
All infants were of the appropriate weight for their gestational age. Exclusion criteria were postnatal steroid administration, chromosomal or other genetic anomalies (e.g., trisomy 21), congenital infections, chronic lung disease, mechanical ventilation or CPAP for more than 24 h, intraventricular hemorrhage, major neonatal illness (e.g., sepsis), maternal history of adrenal illness or endocrine problems, and evidence of maternal substance use during pregnancy (e.g., alcohol). Mothers of the two groups of infants did not significantly differ in age at time of delivery (mean ¼ 28.6, s.d. ¼ 5.9), marital status (65% married) or race (73% Caucasian, 9% African American, 9% Hispanic).
Clinical characteristics
Medical history was obtained through review of patients' medical records. The reason for premature delivery did not differ significantly between the two groups (AB group: 63% PTL, 18% PROM and 10% Other; No AB Group: 66% PTL, 11% PROM and 22% Other). Additional clinical characteristics of the two groups are presented in Table 1 .
Procedure
Infants in the AB group were assessed twice. The first assessment occurred between postnatal days 3 and 5 (mean ¼ 4.3 days) to allow cortisol levels to stabilize after the response to birth. At this first assessment infants were between 28 and 30 weeks postconceptional age (PCA). The second assessment occurred when they reached 33-34 weeks PCA. The No AB group was also evaluated at 33-34 weeks PCA allowing for comparison of the two groups matched for PCA. The study design is shown in Table 2 . Each 2-h assessment consisted of two phases and began 60 min after the feeding that occurred between 0400 and 0700. During the first phase, infants were monitored continuously for 1-h to ensure that they were not handled and that they remained in either quiet or active sleep. The second phase began with resting baseline measurements. During the 5-min resting baseline, HR and behavioral state were recorded. Resting baseline salivary cortisol was then assessed, followed by a clinically indicated heelstick blood draw. Heart rate and behavioral assessments continued during the heelstick and the 5-min recovery period. Salivary cortisol samples collection began at 20 and 40 min after the start of the heelstick.
Measures Salivary cortisol. Saliva was obtained (without any stimulant) by placing a Q-tipt cotton swab in the infant's mouth for 5 min. This collection method does not interfere with the cortisol assay. 5 Furthermore, saliva samples can be collected in this manner without disturbing or waking the infant. Saliva samples were collected prior to the heelstick (baseline), and at 20 min (response) and 40 min (recovery) after the heelstick. Salivary cortisol reflects the unbound or active fraction of cortisol and is highly correlated with plasma cortisol in premature and full term newborns and adults.
11,12 The Q-tip was then placed in a Salivette sampling device (Sarstedt, Numbrecht, Germany). Salivettes were placed into a centrifuge (for 10 min at 4000 Hz) to extract saliva and then frozen at À201C until assayed. Saliva samples were assayed for cortisol determination employing a competitive solid phase timeresolved fluorescence immunoassay with fluorometric end point detection (DELFIA). All of the samples from an infant were included in the same assay batch to eliminate within subject interassay variance. Each batch contained subjects from the AB group and the No AB group. Volume permitting, samples were assayed in duplicate and averaged. Sixty-eight percent of the samples were assayed in duplicate. The inter-assay and intra-assay coefficients of variance were 11.99 and 4.30, respectively.
Heart rate. Either a Space Labs or an Air Shields monitor was used to record infant HR. Heart rate was retained for the purposes of this study at 30-s intervals during a 5-min resting baseline period just prior to the heelstick (baseline), during the heelstick (response), and during the 5-min recovery period (recovery). Mean HR was calculated for each of the three periods.
Behavioral state. Videotapes obtained for this purpose were coded for behavioral state during the resting baseline period, the heelstick, and the recovery period. Behavioral state was assessed using a modified version of a coding system designed for premature infants. 13 This scheme was used to categorize each infant's state: quiet sleep, active sleep, quiet awakeness/drowsy, awake and alert, fussy, and crying. Tapes were coded in 10-s epochs. Codes recorded represented the highest level of state or activity noted during each 10-s epoch. Percent agreement for state codes, obtained on 20% of the tapes, was 92.9%. Infants' average state score during the resting baseline, heelstick, and recovery periods was calculated.
Statistical analysis
Repeated measures ANOVAs conducted at each PCA assessed whether there was a change in HR, behavior, and cortisol over time (baseline, response, and recovery) in response to the stressor. Planned contrasts for linear and quadratic trends were utilized to evaluate hypotheses for the pattern of responses to this event.
Comparisons between groups in change in HR, behavior and cortisol over time were made using repeated measures ANOVAs with infant group as a between groups factor.
Results
Responses to stress during the first postnatal week in the AB group
The first goal of the study was to examine physiological and behavioral response to a heelstick blood draw during the first postnatal week in AB-treated infants. Heart rate (F(2,26) ¼ 18.1, P ¼ 0.0001) and behavior (F(2,26) ¼ 11.6, P ¼ 0.0001) changed significantly in response to the heelstick and, as shown in Figure  1a and b, were higher during the heelstick as compared to baseline and recovery [HR: F(1,13) ¼ 51.5, P ¼ 0.0001 and behavioral distress: F(1,13) ¼ 16.1, P ¼ 0.001]. In contrast, cortisol levels did not change significantly in response to the heelstick, F(2,26) ¼ 2.5, P ¼ 0.10). There was a nonsignificant trend for a decrease in cortisol in response to the heelstick (F(1,13) ¼ 3.3, P ¼ 0.095; See Figure 1c ). Thus while AB-treated infants responded to a painful stressor with increases in HR and behavioral distress, a cortisol response to this stressor was not observed during postnatal week 1.
Responses to stress 4-6 weeks after birth in the AB group Infants continued to respond to the heelstick with a significant change in HR, F(2,26) ¼ 28.7, P ¼ 0.0001, and behavioral distress F(2,26) ¼ 9.32, P ¼ 0.001. Again HR and distress were higher during the heelstick as compared to baseline and recovery [HR: F(1,13) ¼ 61.5, P ¼ 0.0001 and behavioral distress: F(1,13) ¼ 12.7, P ¼ 0.004; See Figure 2a and b]. Similar to postnatal week 1 infants did not display a significant change in cortisol, F(2,26) ¼ 3.0, P ¼ 0.07. Again, as shown in Figure 2c , there was a non significant trend for a decrease in cortisol relative to baseline levels in response to the heelstick, F(1,13) ¼ 3.0, P ¼ 0.07. These data indicate that although AB-treated infants responded to a painful stressor with increases in HR and behavioral distress the cortisol response to this stressor was still not observed 4-6 weeks after birth.
Comparison between the AB and No AB groups at 33-34 weeks PCA We next examined how the pattern of physiological and behavioral responses in AB-treated infants compared to infants at the same PCA without AB treatment.
Heart rate. The groups differed significantly in HR across measurement periods with the AB group displaying higher HR, F(1,21) ¼ 16. Behavioral state. Behavioral state also changed in response to the heelstick (F(2,42) ¼ 14.7, P ¼ 0.0001), however, the two groups did not differ in the pattern of behavioral responses. Behavioral distress (F(1,13) ¼ 26.5, P ¼ 0.0001) was higher during the heelstick as compared to baseline and recovery for both groups (See Figure 2b) .
Cortisol. The groups differed significantly in cortisol levels across measurement periods with the AB group displaying lower cortisol, F(1,21) ¼ 6.9, P ¼ 0.016. Additionally, there was a significant interaction between group and cortisol levels in response to the heelstick, F(2,42) ¼ 3.8, P ¼ 0.031. As shown in Figure 2c , whereas the No AB group displayed the expected increase in cortisol as compared to baseline, the AB group did not, F(1,13) ¼ 5.7, P ¼ 0.026. These data demonstrate that AB-treated infants displayed similar behavioral and larger HR responses as compared to nontreated infants matched for PCA. In contrast, while the No AB group displayed increases in cortisol in response to the heelstick the AB treatment group did not.
Discussion
Previous studies have shown suppression of the HPA axis both at baseline and in response to a physiologic stressor during the first postnatal week following AB therapy. 5, [7] [8] [9] Although these studies demonstrated a return to normal baseline cortisol levels within a week after AB treatment, no previous studies have assessed the persisting consequences of AB exposure on the response to a physiologically relevant stressor. Evaluating such responses provides important information about HPA axis functioning. This is a different assessment than the CRH or ACTH stimulation tests that provides a better indication of the ability of the HPA axis to function in its normal biological capacity. Using this method, we found that abnormalities in HPA axis regulation remain 4-6 weeks after birth in infants treated with AB. Furthermore, although behavioral responses did not differ between the two groups, HR at baseline and in response to the stressor was elevated in the AB group. The greater HR response of AB-treated infants may reflect a compensatory response to the suppression of HPA axis activity. Alternatively this elevation in HR could reflect sensitization of the HR response after repeated exposures to painful stressors in the NICU.
An ideal study would have included a second comparison group, infants born at 28-30 weeks of gestation without AB treatment. However, this group is exceedingly rare in the current climate of treating mothers in preterm labor at 28-30 weeks with betamethasone. Furthermore, an important criterion for inclusion in this study was the lack of postnatal illness to ensure that postnatal stress (associated with such illness) would not confound the cortisol data. Any infant born at 28-30 weeks GA without prenatal AB treatment is at a high risk of developing neonatal lung disease. Considering these factors, this potential control group could not included. However, it is important to note the significant differences between infants born at 34 weeks GA and those who are 34 weeks PCA, but have been living in the extrauterine environment of the NICU for 4-6 weeks. Without a comparison group matched for GA at delivery two alternative explanations for the findings presented here cannot be eliminated. One possibility is that the pattern of cortisol production seen during week 1 is the normal response for infants at 28-30 weeks gestational age who may already be dealing with a high level of stress given the challenges of even the baseline NICU environment. We believe that this interpretation is unlikely given that the pattern displayed by these infants is similar to the blunted cortisol response displayed by AB-treated infants born at later gestational ages. 5 A second alternative explanation is that the blunted cortisol response at four to six postnatal weeks could potentially reflect habituation to the heelstick procedure, rather than suppression resulting from AB exposure. This explanation is unlikely for two reasons. First, The AB group displayed an enhanced HR response indicating that they had not habituated to this event. Second, previous studies have demonstrated that infants become sensitized to repeated heelstick blood draws, showing a greater increase in cortisol to subsequent exposures to this procedure. 14 These data demonstrating that AB treatment has an impact on fetal development, with lasting consequences for postnatal regulation of the HPA axis, are consistent with animal models. In rodents prenatal GC treatment blunts the HPA axis response in the offspring during the neonatal period. 15 Furthermore, fetal exposure to GCs leads to lifelong alterations in HPA axis functioning. 16, 17 Similarly, sheep and primate studies have demonstrated that a synthetic GC treatment, modeled after the regimen currently given to pregnant women, alters HPA responsiveness in the offspring at up to 1 year of age. [18] [19] [20] Studies with animal models further indicate that consequences of prenatal GC treatment are dependent on the timing of exposure. Infants in the current study were exposed to AB between 27 and 29 weeks of gestation. Examination of the consequences of AB when administered at other gestational ages would be useful to determine whether outcome differs depending on the timing of exposure. Evidence suggests that this prenatal programming of the HPA axis involves modification of GC feedback regulation. Prenatal GC treatment alters GC receptor development and CRH mRNA in the paraventricular nucleus (PVN) and hippocampus (involved in negative feedback containment) and the amygdala (involved in activation) of the HPA axis. 16, 17, 21 The suppressive effect of AB treatment on the HPA axis may pose consequences for the health of the preterm infant during the NICU stay and potentially after discharge. Future studies are needed to examine whether the inability to produce sufficient cortisol in response to stimulation limits infants' ability to manage challenges possibly placing them at greater risk for the negative effects of infectious and noninfectious stressors they encounter in intensive care or after discharge. 22 Another potential concern relates to the hypothesis that adverse events in utero alter the trajectory of development with consequences for adult health. 23, 24 Fetal exposure to GCs has been proposed as one mechanism that may underlie prenatal programming. 17, 25 Although GCs are necessary for normal development, excess exposure has deleterious consequences for fetal growth and in animal models leads to the development of permanent hypertension, hyperglycemia, and hyperinsulinemia. 16, [26] [27] [28] Whether the dose and timing of exposure with prenatal betamethasone is sufficient to induce long-term programming changes remains unknown, but must be considered.
These data do not suggest that clinical administration of corticosteroids is contraindicated. There is significant evidence that a single dose of AB reduces mortality among premature infants. 29 Data from the current study should be interpreted with caution. Although the 2 study groups did not significantly differ in the reason for preterm delivery or postnatal health, administration of AB was not determined by random assignment. Furthermore, a control group born at 28-30 weeks of gestation was not included. These data do illustrate the necessity of longer-term follow-up studies to examine the extent and duration to which this alteration in HPA axis functioning continues through infancy and early childhood and the ensuing consequences for health and development.
